

Lupin recalls Quinapril tablets from US market

Hyderabad, Jan 29: Pharmaceutical major Lupin has said its US subsidiary, Lupin Pharmaceuticals, has initiated voluntary recall of multiple lots of Quinapril tablets USP from the US market after failing a impurity specification test.

According to information available with the US FDA, the recall was initiated by the company last September, and as many as 53,160 bottles of both the drugs are being recalled under Class-II classification.

In 2006, Lupin received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Quinapril Tablets USP in 5 mg, 10 mg, 20 mg and 40 mg strengths. *PTI*

Regulatory / Company